Country for PR: China
Contributor: PR Newswire Asia (China)
Tuesday, May 14 2019 - 20:19
AsiaNet
BGI Genomics and Pryzm Health Form Strategic Partnership to Advance Precision Public Health
SHENZHEN, China, May 14, 2019 /PRNewswire-AsiaNet/ --

BGI Genomics and digital health start-up, Pryzm Health (Pryzm), signed a 
Memorandum of Understanding (MoU) today for collaboration to advance precision 
public health in Australia. 

BGI Genomics and digital health start-up, Pryzm Health (Pryzm), signed a 
Memorandum of Understanding (MoU) today for collaboration to advance precision 
public health in Australia. 

Pryzm is an innovative digital health start-up focused on guiding personal and 
clinical health decisions by accelerating diagnosis of rare and inherited 
diseases. The collaboration with BGI Genomics aims to improve the utility of 
cost-effective genomic testing for the clinic and lower the barriers for access 
to precision healthcare in Australia by harnessing the synergy between the 
complementary technologies of BGI Genomics in genomics and Pryzm in the 
integration and analytics of genomic information and electronic health data. 

"Australia has a world-class health system, and significant capability in 
genomics research and in the application of genomics data in clinical practice. 
The Pryzm team has world-recognized capabilities in genome analytics and 
phenomics. Pryzm and BGI Genomics are a perfect match with our complementary 
skills in population-scale genome sequencing. We are thrilled to join forces 
with Pryzm and to explore the combined power of genomics and phenomics with 
Pryzm to improve patient outcomes and enhance public health," said Dr Ning Li, 
Chief Development officer of BGI Genomics.

Photo - https://photos.prnasia.com/prnh/20190514/2465951-1
(Caption: BGI Genomics and Pryzm Form Strategic Partnership in Precision Public 
Health)

In Australia, the use of genetic information in mainstream health practice is 
gaining support from the government, industry and scientific and clinical 
communities. Last year, the Australian government announced a 10-year AUD 500M 
fund to advance the use of genomics in health. 

"Despite the well-known benefits of genomics to improve patient outcomes, 
access to genomic information in healthcare remains limited. This partnership 
will pave the way to make this transformational technology and information 
available to all those that need it - particularly those affected by rare or 
undiagnosed conditions," said Pryzm's co-Founder, Dr Marcel Dinger. 

"One of the key limitations in realising the value of genomic data in both 
research and clinical practice is access to structured and high-quality 
phenotypic data. Pryzm's core capabilities of acquiring and classifying 
clinical features and symptoms will meet a critical need for accelerating 
routine use of genomic data in healthcare settings. Our expertise will also 
ensure the privacy and security of health data," added Pryzm co-founder, Dr 
Tudor Groza.

BGI Genomics
BGI Genomics, a subsidiary of BGI, provides a wide range of next generation 
sequencing services and a broad portfolio of genetic tests for medical 
institutions, research institutions and other public and private partners. 
BGI's mission is to leverage its genomics expertise in order to advance life 
science research and improve human health for the benefit of mankind. BGI is 
headquartered in Shenzhen, China, with branches and medical laboratories in 
major cities including Beijing, Tianjin, Wuhan, Shanghai and Guangzhou. BGI 
also has offices and laboratories located in Europe, North America and the Asia 
Pacific region. BGI currently operates in more than 100 countries and regions 
and works with more than 3,000 medical institutions and more than 300 hospitals.

Pryzm Health
Pryzm is a digital health company focused on identifying and accelerating 
patient diagnosis, particularly of rare and inherited diseases. Pryzm fulfils 
its mission by developing secure and clinically-compliant software to support 
phenotyping and phenotype analysis to serve patients and the healthcare 
industry. 

SOURCE:  BGI Genomics

Image Attachments Links:
http://asianetnews.net/view-attachment?attach-id=336040